NICE rejects Pfizer’s rare heart disease treatment Vyndaqel by Lucy Parsons | May 12, 2021 | News | 0 The final guidance publication comes following an appeal against earlier draft recommendations Read More
Vyndaqel first treatment approved in Europe for ATTR-CM by Anna Smith | Feb 19, 2020 | News | 0 The decision was based on results from the Phase III ATTR-ACT study. Read More
Pfizer’s Vyndaqel, Vyndamax win US nod for rare disease by Anna Smith | May 8, 2019 | News | 0 The approval is based on a clinical trial which showed that after an average of 30 months, the survival rate was higher in the Vyndaqel group. Read More
Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows by Selina McKee | Aug 9, 2016 | News | 0 A new analysis of data pooled from three clinical trials backs early intervention with Pfizer’s Vyndaqel in patients with the rare neurodegenerative disease transthyretin familial amyloid polyneuropathy (TTR-FAP). Read More